(PharmaNewsWire.Com, May 13, 2017 ) Bile duct cancer (cholangiocarcinoma) is the presence of mutated epithelial cells that originate in the bile ducts. Though, cause of bile duct cancer (cholangiocarcinoma) is not certain. There are several factors that can enhance chances of developing bile duct cancer (cholangiocarcinoma). According to American Society of Clinical Oncology (ASCO), fewer than 3,000 people are affected with the disease annually in the U.S. and around 1,600 people are affected by the disease in the U.K., according to Cancer Research United Kingdom. Major indications of cholangiocarcinoma include abnormal liver function, abdominal pain, weight loss, generalized itching, discoloration of stool and urine etc. Causes of cholangiocarcinoma are not known but factors such as exposure to thorium dioxide, liver fluke infections and cholangitis have been known to increase the chances.
Bile duct cancer (cholangiocarcinoma) treatment market is driven by the technological advancement in healthcare sector and increase in prevalence of cancer patients across the globe. Also, enhanced emphasis of pharmaceutical companies on R&D to come up with potential treatment for bile duct cancer (cholangiocarcinoma). However, high cost associated with latest clinical trials and approvals act as a major barrier for global bile duct cancer (cholangiocarcinoma) treatment market.
Global bile duct cancer (cholangiocarcinoma) treatment market is classified on the basis of disease indication, by treatment type and geography.
Due of the availability of variety of chemotherapeutic agents for the bile duct cancer (cholangiocarcinoma) treatment, market for chemotherapeutic agents is expected to hold a greater share in global bile duct cancer (cholangiocarcinoma) treatment market. Innovative bile duct cancer (cholangiocarcinoma) treatment procedures are expected to launch into the market in the forecast period.
Depending on geographic region bile duct cancer (cholangiocarcinoma) treatment market is segmented into five key regions: North America, Latin America, Europe, Asia Pacific, and Middle East & Africa. North America accounts maximum in global bile duct cancer (cholangiocarcinoma) market share. Market for bile duct cancer (cholangiocarcinoma) treatment is maximum in North America due to advanced healthcare facilities, adequate reimbursement policies and greater awareness towards health care. Europe and Asia-Pacific market is expected to register a healthy CAGR over the forecast period.
Some of the key players in bile duct cancer (cholangiocarcinoma) are Johnson & Johnson Services, Inc., ConMed Corporation, W. L. Gore & Associates, Inc., Dispomedica GmbH, InSitu Technologies Inc., Boston Scientific Corporation, Medtronic Plc, Pauldrach medical Handels- und Vertriebs GmbH, OptiMed Medizinische Instrumente GmbH among several others.
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including:
